Emilvon Remedies Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.50 M
- Company Age 8 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.00 M
About Emilvon Remedies
Emilvon Remedies Private Limited (ERPL) is a Private Limited Indian Non-Government Company incorporated in India on 22 February 2016 (Eight years and 11 months 10 days old ). Its registered office is in Ranchi, Jharkhand, India.
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹1.00 M.
Anil Kumar and Vijay Prasad serve as directors at the Company.
Company Details
-
Location
Ranchi, Jharkhand, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U70109JH2016PTC003561
-
Company No.
003561
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
22 Feb 2016
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Jharkhand
Industry
What products or services does Emilvon Remedies Private Limited offer?
Emilvon Remedies Private Limited offers a wide range of products and services, including Pantoprazole Drugs, Pantoprazole Tablets, Mineral Supplement, Calcium Tablet, Vitamin Tablets & Capsules, Methylcobalamin Tablets.
Who are the key members and board of directors at Emilvon Remedies?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Anil Kumar
|
Director | 22-Feb-2016 | Current |
|
Vijay Prasad
|
Director | 17-Nov-2021 | Current |
Financial Performance of Emilvon Remedies.
Emilvon Remedies Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Emilvon Remedies?
In 2017, Emilvon Remedies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.00 M
₹0
Charges Breakdown by Lending Institutions
- Syndicate Bank : 0.10 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 19 Dec 2016 | Syndicate Bank | ₹1.00 M | Open |
How Many Employees Work at Emilvon Remedies?
Unlock and access historical data on people associated with Emilvon Remedies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Emilvon Remedies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Emilvon Remedies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
